AbbVie (ABBV) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.08%. A quarter ago, it was expected that this drugmaker would post earnings of $2.89 per share when it actually produced earnings of $2.97, delivering a surprise of +2.77%.Over the last four quarters, the company has surpas ...

Eli Lilly (LLY) came out with quarterly earnings of $7.02 per share, beating the Zacks Consensus Estimate of $6.02 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.61%. A quarter ago, it was expected that this drugmaker would post earnings of $5.61 per share when it actually produced earnings of $6.31, delivering a surprise of +12.48%.Over the last four quarters, the company has ...

Merck (MRK) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.32%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.01 per share when it actually produced earnings of $2.13, delivering a surprise of +5.97%.Over the last four quarters, the comp ...

Core Insights - Innoviva (INVA) shares increased by 5.5% to close at $18.35, following a notable trading volume that exceeded typical levels, contrasting with an 8.9% loss over the past four weeks [1][2] Company Performance - The price surge is linked to rising investor confidence in Innoviva's core royalties portfolio, the growing momentum of its marketed products from the infectious disease platform, and strategic investments in healthcare assets [2] - Innoviva is projected to report quarterly earnings of $0.46 per share, reflecting a year-over-year increase of 2200%, with expected revenues of $93.92 million, up 4.9% from the previous year [3] - The consensus EPS estimate for Innoviva has remained stable over the last 30 days, indicating that stock price movements typically require trends in earnings estimate revisions [4] Industry Context - Innoviva holds a Zacks Rank of 3 (Hold) within the Large Cap Pharmaceuticals industry, while Novo Nordisk (NVO), a peer in the same sector, experienced a 2.6% decline to $53.38 and has returned -8% over the past month [5] - Novo Nordisk's consensus EPS estimate has decreased by 4.2% over the past month to $0.75, representing a year-over-year change of -16.7%, and it currently holds a Zacks Rank of 4 (Sell) [6]

Novo Nordisk (NVO) ended the recent trading session at $53.38, demonstrating a -2.56% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.53%. Elsewhere, the Dow lost 0.71%, while the tech-heavy Nasdaq lost 0.93%. The drugmaker's stock has dropped by 7.99% in the past month, falling short of the Medical sector's gain of 3.64% and the S&P 500's gain of 1.13%.The upcoming earnings release of Novo Nordisk will be of great interest to investors. The co ...

Core Viewpoint - Pfizer's upcoming earnings report is anticipated to show a significant decline in earnings and revenue compared to the previous year, raising investor interest [2][3]. Group 1: Stock Performance - Pfizer's stock increased by 1.16% to $24.51, outperforming the S&P 500's daily gain of 0.53% [1]. - Over the past month, Pfizer's stock has risen by 0.33%, which is below the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71% [1]. Group 2: Earnings Estimates - Analysts expect Pfizer to report earnings of $0.68 per share on November 4, 2025, reflecting a year-over-year decline of 35.85% [2]. - The Zacks Consensus Estimate for Pfizer's revenue is projected at $16.81 billion, down 5.06% from the previous year [2]. Group 3: Full Year Projections - For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and revenue of $63.4 billion, indicating changes of -1.29% and -0.36% respectively from the prior year [3]. Group 4: Analyst Revisions and Rankings - Recent changes to analyst estimates for Pfizer are crucial as they reflect short-term business trends, with positive revisions indicating analyst optimism [3][4]. - Pfizer currently holds a Zacks Rank of 3 (Hold), with a 1.87% decline in the Zacks Consensus EPS estimate over the past month [5]. Group 5: Valuation Metrics - Pfizer's Forward P/E ratio is 7.88, significantly lower than the industry average of 14.5, suggesting it is trading at a discount [6]. - The PEG ratio for Pfizer is 0.8, compared to the industry average of 1.59, indicating a favorable valuation relative to expected earnings growth [6]. Group 6: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [7]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7].

AbbVie (ABBV) closed the most recent trading day at $226.22, moving -1.27% from the previous trading session. This move lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 0.66%. Shares of the drugmaker have appreciated by 5.95% over the course of the past month, outperforming the Medical sector's gain of 1.8%, and the S&P 500's gain of 1.02%.The upcoming earnings release of AbbVie will be of great interest to investors. The company's earnings report is ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.8 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.08%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.66 per share when it actually produced earnings of $2.77, delivering a surprise of +4.14%.Ove ...

Core Insights - Johnson & Johnson (JNJ) has a strong track record of beating earnings estimates, particularly in the last two quarters with an average surprise of 5.96% [1] - The company reported earnings of $2.66 per share for the most recent quarter, falling short of the expected $2.77 per share, resulting in a surprise of 4.14% [2] - For the previous quarter, JNJ exceeded expectations by reporting $2.77 per share against a consensus estimate of $2.57, achieving a surprise of 7.78% [2] Earnings Estimates and Predictions - Recent estimates for Johnson & Johnson have been trending upwards, with a positive Earnings ESP (Expected Surprise Prediction) indicating a potential earnings beat [5] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better has historically led to a positive surprise rate of nearly 70% [6] - Johnson & Johnson currently has an Earnings ESP of +1.53%, suggesting analysts are optimistic about the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Johnson & Johnson is expected to be released on October 14, 2025 [8]

Merck (MRK) ended the recent trading session at $87.61, demonstrating a -1.34% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced a drop of 0.2%, and the technology-dominated Nasdaq saw a decrease of 0.67%. The stock of pharmaceutical company has risen by 5.6% in the past month, leading the Medical sector's gain of 2.72% and the S&P 500's gain of 4.06%.Analysts and investors alike will be keeping a ...